Beijing HebaBiz Biotechnology

HebaBiz Biotech is a biopharmaceutical company founded in 2011 by Yale University scholars, including founder Dr. James Zhou. Headquartered in Beijing, the company specializes in developing innovative therapies for cancers and liver diseases by integrating biotechnology with traditional Chinese medicine. Its clinical pipeline features Siroquine (JP001), a dual autophagy modulator for glioblastoma, and Clevudine (L-FMAU), a nucleoside analog in Phase 3 trials for chronic hepatitis B. HebaBiz operates a large-scale manufacturing facility in Guangxi and utilizes a proprietary Mechanism of Action (MOA) research platform to drive drug discovery. The company maintains a commercial presence with over 80 product approvals and strategic partnerships with academic institutions like Yale and PolyU.